Brief Opinion

The Case for Brachytherapy: Why It Deserves a Renaissance

Vonetta M. Williams, MD,a,1 Jenna M. Kahn, MD,b,1 Nikhil G. Thaker, MD,c Sushil Beriwal, MD,d Paul L. Nguyen, MD,e Douglas Arthur, MD,f Daniel Petereit, MD,g and Brandon A. Dyer, MDa,*

aDepartment of Radiation Oncology, University of Washington, Seattle, Washington; bDepartment of Radiation Oncology, Oregon Health & Science University, Portland, Oregon; cDepartment of Radiation Oncology, Arizona Oncology, Tucson, Arizona; dDepartment of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania; eDepartment of Radiation Oncology, Dana-Farber/ Harvard Cancer Center, Boston, Massachusetts; fDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia; and gDepartment of Radiation Oncology, Monument Health Cancer Care Institute, Rapid City, South Dakota

Received 21 June 2020; revised 16 September 2020; accepted 13 October 2020

Abstract

The recent global events related to the coronavirus disease of 2019 pandemic have significantly changed the medical landscape and led to a shift in oncologic treatment perspectives. There is a renewed focus on preserving treatment outcomes while maintaining medical accessibility and decreasing medical resource utilization. Brachytherapy, which is a vital part of the treatment course of many cancers (particularly prostate and gynecologic cancers), has the ability to deliver hypofractionated radiation and thus shorten treatment time. Studies in the early 2000s demonstrated a decline in brachytherapy usage despite data showing equivalent or even superior treatment outcomes for brachytherapy in disease sites, such as the prostate and cervix. However, newer data suggest that this trend may be reversing. The renewed call for shorter radiation courses based on data showing equivalent outcomes will likely establish hypofractionated radiation as the standard of care across multiple disease sites. With shifting reimbursement, brachytherapy represents the pinnacle in hypofractionated, conformal radiation therapy, and with extensive long-term data in support of the treatment modality brachytherapy is primed for a renaissance.

Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Sources of support: There are no funding sources to disclose.

Disclosures: The listed authors declare no actual or potential conflicts of interest. There were no grants, monies, or other financial incentives or coercions used or offered in the preparation of this manuscript. This manuscript has not been presented or published, in part or in full, before this submission. Dr Paul L. Nguyen has consulted for Ferring, Janssen, Astellas, Bayer, Nanobiotix, Boston Scientific, Augmenix, Blue Earth, Cota, and Dendreon, and has received research funding from Janssen, Bayer, and Astellas. Dr Daniel Petereit has received funding from the following foundations and the National Cancer Institute to support his cancer disparity program, Walking Forward: Bristol-Myers Squibb Foundation, Polo Ralph Lauren Foundation, Irving A Hansen Memorial Foundation, and the National Institutes of Health (R01CA240080-01). Dr Nikhil G. Thaker reports personal fees from McKesson Specialty Health. Dr Sushil Beriwal has consulted for Varian and reports personal fees from Via Oncology. Dr Douglas Arthur has consulted for Advanced Radiation Therapy, Inc.

* Corresponding author: Brandon A Dyer, MD; E-mail: badyer@uw.edu

1 Co-first authors.

https://doi.org/10.1016/j.adro.2020.10.018
2452-1094/Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction

Given recent global events related to the coronavirus disease of 2019 (COVID-19) pandemic, the medical landscape and oncologic treatment perspectives have significantly shifted. Oncologic physicians are increasingly focused on maintaining equipoise of treatment outcome and medical accessibility with decreasing medical resource utilization. In support of these measures, radiation oncologists have used a variety of temporizing measures, including hormone therapy measures (eg, breast, endometrial, and prostate cancer), treatment delays (where appropriate), and hypofractionation across all disease sites.1-5 For breast, prostate, and gynecologic malignancies, low-dose rate (LDR) and high-dose-rate (HDR) brachytherapy represent the pinnacle of hypofractionated, conformal radiation therapy. Previously, studies showed a decline in both gynecologic6,7 and prostate8 brachytherapy despite data showing superior treatment outcomes. However, newer data suggest that the declining utilization rates may be reversing.9,10 Brachytherapy treatment approaches are well tolerated, safe, effective, and cost-effective. As radiation oncologists and patients move forward, brachytherapy represents an often underused and effective treatment modality.

Gynecologic Brachytherapy

Gynecologic brachytherapy is a vital and irreplaceable component of definitive and adjuvant treatment for gynecologic malignancies. Multiple studies have demonstrated the efficacy of brachytherapy to treatment outcomes in cervical and uterine oncologic malignancies.11-19 Unfortunately, gynecologic brachytherapy utilization has declined in parallel with the clinical implementation of intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy.5,7 Furthermore, attempts to replace brachytherapy with external beam treatment approaches have been unsuccessful. Notably, a recent phase 2 study of patients with predominantly locally advanced cervical cancer examined the feasibility of using a SABR boost as an alternative option to brachytherapy for medically unfit patients or those who refuse brachytherapy.20 The study was closed early owing to high toxicity rates, including death due to complications of therapy. The cervical cancer clinical practice guidelines by the American Society for Radiation Oncology state that either SABR or IMRT are only suitable replacements for brachytherapy when considered for patients refusing or ineligible for brachytherapy.21

Modern HDR brachytherapy is a form of hypofractionated, conformal therapy commonly delivered in 4 to 5 treatments for cervical cancer.22 However, there are 2- and 3-fraction regimens23,24 that have been used more in resource-poor settings that can be used to preserve resources in these times, decreasing the treatment time so that curative treatment can be delivered faster. Complex interstitial cases are often done in the operating room in the modern era, but gynecologic brachytherapy procedures can be safely delivered without use of operating room time in an HDR suite without the need for anesthesia or through the use of moderate sedation for interstitial cases.

Advances in imaging technology, such as magnetic resonance imaging, allow for adaptive image guided brachytherapy (IGBT) with simultaneous dose escalation to tumor targets and sparing of organs at risk. Compared with point-based brachytherapy planning, volumetric-based planning using IGBT has demonstrated improved tumor control and significantly reduced toxicity.25-27 Additionally, a cost-utility analysis of IGBT showed that magnetic resonance imaging has the potential to decrease health care costs compared with 2-dimensional or computed tomography—guided brachytherapy through reduced costs from cancer recurrence and treatment toxicity.28

Breast Brachytherapy

Partial breast irradiation (PBI) has demonstrated comparable treatment outcomes to whole breast irradiation with regard to local tumor control, toxicity, and cosmetic outcomes.29-33 Initially, accelerated PBI provided a method to shorten typical 5- to 6-week standard fractionation radiation courses to 5 days. The recent publication of the UK Fast Forward study offers an even faster external beam option for the delivery of radiation to the breast.34 However, hypofractionation is still underused in the United States.35 Therefore, brachytherapy remains a viable, short treatment option with new data exploring noninvasive techniques and even shorter treatment regimens.36,37

Early data for breast brachytherapy delivered in 1 to 4 fractions have demonstrated excellent local tumor control and cosmetic outcomes.37,38 The phase 2 Triumph-T trial showed excellent local tumor control (albeit with a short median follow up) and breast cosmesis using a 3-fraction breast brachytherapy technique, and a similar 4-fraction regimen had excellent cosmesis with no locoregional recurrences at 6 years.37,39 Furthermore, in elderly patients, single-fraction regimens have also demonstrated excellent oncologic outcomes,40 and a recent study comparing PBI with PBI + hormone therapy or hormone therapy alone in women age >70 years with low-risk, hormone-positive, early stage breast cancer demonstrated that PBI was superior when compliance with hormone therapy was poor,41 and tested compliance interventions have demonstrated no improvement.42,43 Therefore, even with the likely adoption of shorter external beam radiation treatment regimens, breast
Prostate brachytherapy

Prostate brachytherapy results in excellent treatment and toxicity outcomes has a short overall treatment time (OTT), and is more cost effective than other radiation treatment options. Prostate brachytherapy (HDR or LDR) is considered equivalent to radical prostatectomy and external beam radiation for the treatment of prostate cancer and can be completed in 1 (LDR) or several (HDR) implantations. The use of either LDR or HDR prostate brachytherapy decreases OTT compared with external beam standard fractionation and some hypofractionation schemes when used as a boost. As monotherapy, HDR and LDR approaches have a shorter OTT than SABR, which is typically delivered in 5 to 7 every-other-day fractions.

Brachytherapy as monotherapy is appropriate for patients with low-risk or favorable intermediate-risk disease or as a boost in patients with unfavorable intermediate- and high-risk disease. When used as a boost for patients with unfavorable to high-risk disease, recent data from 2 prospective randomized trials have shown that brachytherapy significantly prolongs biochemical progression-free survival by >50% compared with dose-escalated external beam radiation. Furthermore, retrospective data also suggest that brachytherapy used as monotherapy for low-risk disease can prolong biochemical progression-free survival compared with either surgery or external beam radiation. In addition, the median cost of prostate cancer therapy has been shown to be less with brachytherapy compared with either SABR, IMRT, or proton therapy. A 2013 study by Hayes et al found that brachytherapy was the most effective and least costly initial treatment option for men with low-risk prostate cancer, including men who chose active surveillance. Fortunately, although older data suggested that treatment with prostate brachytherapy was declining, this trend appears to reversing.

Prostate brachytherapy is also useful in the setting of isolated intraprostatic recurrence after definitive treatment with radiation. A recent phase 2 trial, as well as several retrospective studies, demonstrated excellent rates of cancer-free and biochemical recurrence-free survival with brachytherapy and had acceptable, predominantly grades 1 and 2 gastrointestinal and genitourinary toxicity. Compared with other local salvage techniques, such as prostatectomy, high-frequency ultrasound, or cryotherapy, prostate brachytherapy has similar rates of biochemical control at 5 years with lower toxicity rates, such as incontinence and bladder neck stricture.

Economic Considerations

The use of hypofractionation in the United States has been increasing, leading to a decline in radiation oncology departmental revenue through reduced episodic fee-for-service reimbursement. This trend coincided with a period of transition from volume- to value-based care. During this period, the total proportion of U.S. health care payments tied to quality- and cost-focused alternative payment models (APMs) increased from 23% in 2015 to 34% in 2017. The shift to value-based care was further accentuated by the recent Radiation Oncology APM (RO-APM) proposal from the Centers for Medicare and Medicaid Services in 2019.

COVID-19 has since accelerated the transition to extreme hypofractionation, including stereotactic radiation therapy and brachytherapy. After COVID-19, we anticipate the continued use of shorter treatment schedules and modalities that minimize patient exposure to high-cost hospital resources, postoperative care, or hospitalization. Brachytherapy is well-positioned to capitalize on these changes given its high value proposition. Most brachytherapy treatments can be delivered with minimal resources, lower fully loaded treatment delivery costs via time-driven activity-based costing analyses, or in alternative locations, such as ambulatory surgery or freestanding centers. As a low-cost modality, brachytherapy can be associated with less patient insurance and copayment for patients who may be facing unemployment or reduced income, as well as loss of health insurance coverage. Despite these benefits, reduced physician reimbursement for brachytherapy has exacerbated a decline in revenues for practices that are already affected during the pandemic. This places radiation oncology practices at a further financial risk in an already high fixed-cost business.

The adoption of the RO-APM may improve financial stability by providing episodic payments for disease site-specific radiation oncology care. These payments would be tied to average episode reimbursements rather than the volume or modality of service. This APM redesign appropriately attempts to incentivize shorter courses of low-cost, high-quality treatment (ie, brachytherapy). This change would also protect physicians from uncontrollable downside risks, such as from COVID-19, and provide financially stable payments to practices.

However, despite these theoretical benefits, several key changes are necessary to the RO-APM to ensure sustainability of and access to radiation oncology care in the
United States. A practice’s bundled reimbursement in the RO-APM will be closely tied to its historical reimbursements per episode of care. Practices that were early adopters of hypofractionation and high users of cost-effective treatments, such as brachytherapy (ie, efficient practices), will receive lower reimbursements than practices that have been slow adopters of hypofractionation or who have not used cost-effective modalities (ie, inefficient practices). The RO-APM also does not account for the cost of episodes of care that require combination modality therapies, including brachytherapy as a boost, and inadvertently incorporates palliative care episodes in the calculation of bundled rates. Solutions exist that can align incentives in the RO-APM toward high-value cancer care, including brachytherapy without unfairly penalizing efficient practices, which is a win for patients, providers, and society as a whole.

Conclusions

Brachytherapy is vital and irreplaceable for gynecologic malignancies, and results in excellent treatment and toxicity outcomes for breast and prostate malignancies. Brachytherapy is value-based and cost effective. The utilization of brachytherapy declined in the early 2000s, and has been associated with a decrease in resident brachytherapy caseload. The decline in residency brachytherapy training has been identified as a barrier to achieving brachytherapy competence and clinical independence. In an effort to combat the decline in brachytherapy, some resident training centers have instituted brachytherapy simulation workshops to improve resident brachytherapy training, and the American Brachytherapy Society has called for expanded training opportunities. The American Brachytherapy Society initiated a 10-year strategic program to address the declining rates of brachytherapy utilization, referred to as 300 in 10. The goal is to train 30 competent brachytherapists per year over 10 years through a multifaceted approach that includes developing a national brachytherapy curriculum, simulation-based medical education, 2-month fellowships for senior-level residents, a certification process, and maintenance of certification.

Given preexisting inclinations for shorter radiation courses, a new radiation oncology normalcy will likely establish hypofractionated radiation as the standard of care across multiple disease sites. With shifting reimbursement, brachytherapy represents the pinnacle in hypofractionated, conformal radiation therapy, and with extensive long-term data in support of the treatment modality brachytherapy is primed for a renaissance.

References

1. Mohindra P, Beriwal S, Kamrava M. Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic. Brachytherapy. 2020;19:390-400.
2. Williams VM, Kahn JM, Harkenrider MM, et al. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. Brachytherapy. 2020;19:401-411.
3. Guckenberger M, Belka C, Bejzak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. 2020;146:223-229.
4. Zaorsky NG, Yu JB, McBride SM, et al. Prostate cancer radiotherapy recommendations in response to COVID-19. Adv Radiat Oncol. 2020;5:659-665.
5. de Azambuja E, Trapani D, Loibl S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. 2020;5:e000793.
6. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87:111-119.
7. Gill BS, Lin JF, Krivak TC, et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: The impact of new technological advancements. Int J Radiat Oncol Biol Phys. 2014;90:1083-1090.
8. Mahmood U, Pugh T, Frank S, et al. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014;13:157-162.
9. Schad MD, Patel AK, Glaser SM, et al. Declining brachytherapy utilization for cervical cancer patients - Have we reversed the trend? Gynecol Oncol. 2020;156:583-590.
10. Corkum MT, Morton G, Louie AV, et al. Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiother Oncol. 2020;152:42-48.
11. Eifel PJ, Thoms WW, Smith TL, Morris M, Oswald MJ. The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 1994;28:113-118.
12. Viswanathan AN, Cormack R, Rawal B, Lee H. Increasing brachytherapy dose predicts survival for interstitial and tandem-based radiation for stage IIB cervical cancer. Int J Gynecol Cancer. 2009;19:1402-2406.
13. Tandrup K, Eifel PJ, Yashar CM, Potter R, Grigsby PW. Curative radiation therapy for locally advanced cervical cancer: Brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys. 2014;88:537-539.
14. Logsdon MD, Eifel PJ. FIGO IIB squamous cell carcinoma of the cervix: An analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys. 1999;43:763-775.
15. Karlsson J, Dreifaldt AC, Mordhorst LB, Sorbe B. Differences in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy. 2017;16:133-140.
16. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study (vol 92, pg 744, 2004). Gynecol Oncol. 2004;94:241-242.
carcinoma - Clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419-426.

18. Creutzberg CL, van Putten WLJ, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: Multicentre randomised trial. Lancet. 2000;355:1404-1411.

19. Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet. 2010;375:816-823.

20. Gaudet M, Jaswal J, Keyes M. Current state of brachytherapy teaching in Canada: A national survey of radiation oncologists, residents, and fellows. Brachytherapy. 2015;14:197-201.

21. Chino J, Ammannzi CA, Beriwal S, et al. Radiation therapy for cervical cancer: Executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10:220-234.

22. Albuquerque K, Hrycushko BA, Harkenrider MM, et al. Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report. Radiother Oncol. 2019;18:429-436.

23. Patel FD, Kumar P, Karunanidhi G, Sharma SC, Kapoor R. Optimization of high-dose-rate intracavitary brachytherapy schedule in the treatment of carcinoma of the cervix. Brachytherapy. 2011;10:147-153.

24. Souhami L, Corns R, Duclos M, Portelance L, Beriwal S, Al-Hilli Z, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and dose. Radiother Oncol. 2015;110:508-513.

25. Sturdza A, Potter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and dose. Radiother Oncol. 2016;120:428-433.

26. Chiarra-Brunaud C, Barer V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study. Radiother Oncol. 2012;103:305-313.

27. Potter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol-based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy for patients with locally advanced cervical cancer. Radiother Oncol. 2011;100:116-123.

28. Perdizet J, D’Souza D, Skliarenko J, et al. A cost-utility analysis of magnetic resonance (MR) guided brachytherapy versus two-dimensional and computed tomography (CT) guided brachytherapy for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020;107:512-521.

29. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial. Lancet. 2019;394:2155-2164.

30. Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after conservation surgery for patients with early breast cancer (UK IMPORT low trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048-1060.

31. Ott OJ, Steyer V, Hildebrandt G, et al. GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Oncol. 2016;120:119-123.

32. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): A randomised controlled trial. Lancet. 2019;394:2165-2172.

33. Mattiini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol. 2020;JCO2000650.

34. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613-1626.

35. Purkhi RB, Fishman E, Chi W, et al. Association of utilization management policy with uptake of hypofractionated radiotherapy among patients with early-stage breast cancer. JAMA Oncol. 2020;6:839-846.

36. Hopel JT, Leonard KL, Sha S, et al. Phase 2 trial of accelerated partial breast irradiation (APBI) using noninvasive image guided breast brachytherapy (NIBB). Int J Radiat Oncol Biol Phys. 2020;S3026-6014(16):33731-33737.

37. Khan AJ, Chen PY, Yashar C, et al. Three-fraction accelerated partial breast irradiation (APBI) delivered with brachytherapy applicators is feasible and safe: First results from the TRIUMPH-T trial. Int J Radiat Oncol Biol Phys. 2019;104:67-74.

38. Jethwa KR, Park SS, Gonuguntla K, et al. Three-fraction intracavitary accelerated partial breast brachytherapy: Early provider and patient-reported outcomes of a novel regimen. Int J Radiat Oncol Biol Phys. 2019;104:75-82.

39. Wilkinson JB, Chen PY, Wallace MF, et al. Six-year results from a Phase II trial for hypofractionated accelerated partial breast irradiation using a 2-day dose schedule. Am J Clin Oncol. 2018;41:986-991.

40. Hannoun-Levi JM, Lam Cham Kee D, Gal J, et al. Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation (SiFEBI) phase II trial. Brachytherapy. 2020;19:90-96.

41. Ward MC, Vicini F, Al-Hilli Z, et al. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-impotent early-stage breast cancer: A systematic review. Breast Cancer Res Treat. 2020;182:355-365.

42. Hershman DL, Unger JM, Hillyer GC, et al. Randomized trial of text messaging to reduce early discontinuation of adjuvant aromatase inhibitor therapy in women with early-stage breast cancer: SWOG S1105. J Clin Oncol. 2020;JCO1902699.

43. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529-537.

44. Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review. Can Urol Assoc J. 2013;7:463-470.

45. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109:22-29.

46. Vargas CE, Schmidt MQ, Niska JR, et al. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. Adv Radiat Oncol. 2018;3:322-330.

47. Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCEND-RT trial): An analysis of survival endpoints for a
randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys.* 2017;98:275-285.

48. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localized prostate cancer. *Radiother Oncol.* 2012;103:217-222.

49. Mahase SS, D’Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States. *JAMA Netw Open.* 2020;3:e1920471.

50. Hayes JH, Ollendorf DA, Pearson SD, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: A cost-effectiveness analysis. *Ann Intern Med.* 2013;158:853-860.

51. Aaronson DS, Yamasaki I, Gottschalk A, et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. *BJU Int.* 2009;104:600-604.

52. Yamada Y, Kollmeier MA, Pei X, et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. *Brachytherapy.* 2014;13:111-116.

53. Crook JM, Zhang PX, Pisansky TM, et al. A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology/RTOG-0526). *Int J Radiat Oncol Biol Phys.* 2019;103:335-343.

54. Parekh A, Graham PL, Nguyen PL. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: A systematic review. *Semin Radiat Oncol.* 2013;23:222-234.

55. Moore A, Stav I, Den RB, et al. The financial impact of hypofractionated radiation for localized prostate cancer in the United States. *J Oncol.* 2019;2019:8170428.

56. Konski A, Yu JB, Freedman G, Harrison LB, Johnstone PA. Radiation oncology practice: Adjusting to a new reimbursement model. *J Oncol Pract.* 2016;12:e576-e583.

57. Health Care Payment Learning & Action Network. Measuring progress: Adoption of alternative payment models in commercial, Medicaid, Medicare Advantage, and Medicare Fee-for-Service programs. Available at: https://hcp-lan.org/2018-apm-measurement/. Accessed April 6, 2020.

58. Centers for Medicare and Medicaid Services. Radiation oncology model 2019. Available at: https://innovation.cms.gov/innovation-models/radiation-oncology-model. Accessed April 6, 2020.

59. Ning MS, Klopp AH, Jhingran A, et al. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. *Brachytherapy.* 2019;18:445-452.

60. Thaker NG, Ali TN, Porter ME, Feeley TW, Kaplan RS, Frank SJ. Communicating value in health care using radar charts: A case study of prostate cancer. *J Oncol Pract.* 2016;12:813-820.

61. Tumati V, Folkert MR, Lawson S, et al. Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. *Brachytherapy.* 2016;15:341-346.

62. Laviana AA, Ilg AM, Veruttipong D, et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. *Cancer.* 2016;122:447-455.

63. American Society for Radiation Oncology. ASTRO sends COVID-19 impact letter to Congress. Available at: https://www.astro.org/News-and-Publications/What-is-Happening-in-Washington/2020/ASTRO-COVID-19-Impact-Letter. Accessed April 6, 2020.

64. Thaker N, Staggs S, Meghani R. JCO oncology practice discussion & analysis in short. Available at: https://jcoopblog.org/blog/2019/9/12/de-conducting-the-proposed-radiation-oncology-model-patient-methodology-implications-for-practices-and-opportunities-for-improvement. Accessed April 6, 2020.

65. Williams VM, Mansoori B, Young L, Mayr N, Halasz LM, Dyer BA. Simulation-based learning for enhanced gynecologic brachytherapy training among radiation oncology residents. *Int J Radiat Oncol Biol Phys.* 2020;S1538-4721:30200-30202.

66. Zhao S, Francis L, Todor D, Fields EC. Proton therapy versus intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. *Brachytherapy.* 2019;18:445-452.

67. Petereit DG. Vision 2020: American Brachytherapy Society. Available at: https://www.americanbrachytherapy.org/ABS/assets/BrachyNews_Summer_2019.pdf. Accessed April 6, 2020.

68. Peterite DG. American Brachytherapy Society BrachyNews. Available at: https://www.americanbrachytherapy.org/ABS/document-server?cfp=ABS/assets/file/public/brachynews/ABS_BrachyNews_Summer_2019.pdf. Accessed April 6, 2020.